Summary:
- No. There’s no cream, gel or vaccine that stops you catching genital Herpes or passing it on. The “cream” in the headlines in 2009 was a liquid tested on mice, and we found no sign that it was ever tested in people.
- Creams can treat sores or numb the pain, but UK guidelines say antiviral tablets work better.
- Condoms, daily antiviral tablets, avoiding sex during an outbreak and telling partners all lower the risk. If you have a sore, the Better2Know Herpes swab test shows whether it’s Herpes and which type, with results in 5 days.
If you’re looking for a genital Herpes cream that protects you or a partner, you’re not alone. In February 2009, we reported that scientists in the US had developed a cream that could stop genital Herpes spreading. More than 15 years later, it’s fair to ask what happened to it.
In this blog, we explain what that research found, whether any cream prevents or treats genital Herpes today, and what does lower the risk of passing it on.
Can a cream stop you catching or passing on Herpes?
No. UK guidance doesn’t list any cream or gel as a way to avoid catching genital Herpes or passing it on, and there’s no vaccine. The World Health Organization (WHO) describes protective creams and gels as something research is still trying to develop.
The creams you can buy or be prescribed do other jobs:
- cold sore creams: antiviral creams such as aciclovir are sold for cold sores on the lips and face. The UK product information for Zovirax Cold Sore Cream says it must not be used to treat genital Herpes
- prescription antiviral cream: this is licensed to treat Herpes sores on the skin, including genital Herpes. It treats the sores. It isn’t a way to protect a partner
- numbing creams: such as 5% lidocaine, these ease the pain of an outbreak
What was the Herpes cream reported in 2009?
It wasn’t a cream, and the study was in mice. In January 2009, researchers at Harvard Medical School reported a treatment that protected mice from HSV-2, one of the two viruses that cause genital Herpes.
- what it was: short pieces of genetic material, called siRNAs, in a liquid that was placed in the vagina. One switched off a gene the virus needs to copy itself. The other switched off a protein the virus uses to get into cells
- what it showed: the mice were given a dose of the virus that kills most of them. Only 20% of untreated mice survived, compared with 60% to 80% of treated mice
- how long it lasted: about a week
Professor Judy Lieberman, who oversaw the research, was talking about that week of protection when she said:
“This aspect has a real practicality to it. If we can reproduce these results in people, this could have a powerful impact on preventing transmission.”
Her words were conditional. The results would first have to be repeated in people.
What happened to it?
We found no sign that it was ever tested in people, and nothing like it is in use today.
- In 2011, a paper from the same laboratory still described the Herpes result as something done in mice. By then the team was working on HIV, using a different kind of molecule.
- UK guidelines on genital Herpes, updated in 2024, don’t mention a treatment of this kind.
- In 2025, WHO still listed creams and gels that block Herpes among the things researchers are trying to develop.
In 2009 this was an early laboratory result. It hasn’t led to a product for people.
Has any gel worked in people?
One gel showed an effect in one trial, but a second trial didn’t confirm it. The gel contained tenofovir, a medicine used to treat HIV.
- the first trial: women in South Africa who used the gel before and after sex were 51% less likely to catch HSV-2
- the second trial: women in South Africa, Uganda and Zimbabwe were asked to use the gel every day. Overall, it made no difference, and blood tests suggested most of the women weren’t using it
- people who already have Herpes: in a trial of 64 women with HSV-2, the gel didn’t reduce outbreaks
We couldn’t find a tenofovir gel in the UK’s medicines compendium, and UK guidelines don’t mention one.
Do creams treat genital Herpes?
Tablets work better than creams. UK guidelines from the British Association for Sexual Health and HIV (BASHH) say antiviral creams are less effective than tablets, and that using both adds nothing.
- a first outbreak: antiviral tablets, such as aciclovir, started within 5 days of the symptoms appearing
- later outbreaks: these usually settle by themselves. Tablets started as soon as symptoms appear may shorten an outbreak by 1 or 2 days
- frequent outbreaks: the NHS says some people who have more than 6 outbreaks a year may benefit from taking antiviral tablets for 6 to 12 months
- pain: a numbing cream can help
There’s no cure for Herpes, because the virus stays in your body. If you test positive with Better2Know, one of our doctors can advise you on treatment and, where it’s needed, prescribe it. Read more in “How long does a Herpes outbreak last?”
What lowers the risk of passing on Herpes?
Four things lower the risk, and they work best together. None of them is a cream, and none removes the risk completely.
- condoms: in one study, using a condom cut the risk each time a couple had sex by 96% from men to women and, less certainly, by 65% from women to men. Herpes can still be passed on from skin the condom doesn’t cover
- daily antiviral tablets: when the partner with Herpes takes valaciclovir every day, the risk to the other partner roughly halves. In a trial of 1,484 couples, 3.6% of partners caught HSV-2 over 8 months on a dummy tablet, compared with 1.9% on valaciclovir
- no sex during an outbreak: the NHS advises avoiding vaginal, anal and oral sex from the first tingle or itch until the sores have healed
- telling partners: UK guidelines say this may reduce the risk by about 50%
The tablet trial was in heterosexual couples where one partner had HSV-2, so the figures may not apply to everyone. Herpes can also be passed on when there are no symptoms. Read more in “Can you still get an STI if you wear a condom?”
Is a Herpes vaccine or new treatment on the way?
There’s still no vaccine, and the new medicines in trials are tablets, not creams.
- vaccines: none is licensed anywhere in the world. GSK said in September 2024 that its vaccine had failed its trial and would not go further, and Moderna dropped its vaccine in November 2025. BioNTech’s vaccine is at the first stage of testing in people, with no results published yet
- pritelivir: a new kind of antiviral tablet for people with weakened immune systems whose Herpes doesn’t respond to standard treatment. Its maker applied for approval in the US in 2026
- once-weekly tablets: another new antiviral, designed to be taken once a week by people with repeat outbreaks, is expected to start its next trial by the end of 2026
These medicines are designed to treat Herpes. They aren’t a way to avoid catching it. Read more in “Australia could produce HSV-2 cure”
Which test do you need?
Better2Know offers:
- Herpes Simplex Type 1 and 2 (Swab): a swab from a sore or blister on your genitals or mouth that shows whether it’s caused by Herpes 1 or Herpes 2, with results in 5 days. You can book it at one of our clinics, have a nurse visit you or order a home test kit.
- Blemish Screen: if you’re not sure what a sore or lump is, it tests a swab for Herpes 1, Herpes 2, HPV and Syphilis, with results in 5 days. You can also order a home test kit.
A swab works best while the sore is there, so it’s worth testing as soon as you notice one. Not sure which test you need? Our Patient Care Team is available 24/7 on 020 7099 0955.
FAQs
Can you use cold sore cream on genital Herpes?
No. The UK product information for Zovirax Cold Sore Cream says it’s only for cold sores on the mouth and face, and must not be used to treat genital Herpes. Using it doesn’t protect a partner either.
How common is genital Herpes?
Very common. WHO estimates that about 846 million people aged 15 to 49 are living with genital Herpes, which is more than 1 in 5. In England, there were 28,779 diagnoses of a first episode in 2025.
Which virus causes genital Herpes?
Either of the two Herpes simplex viruses. HSV-1, which also causes cold sores, is now the most common cause of genital Herpes in the UK. Read more in “Oral vs genital Herpes: what’s the difference?”
Final thoughts
The cream that made headlines in 2009 was an early result in mice, and it never became a product. Today there’s still no cream, gel or vaccine that prevents genital Herpes. What does lower the risk is using condoms, daily antiviral tablets for the partner who has Herpes, avoiding sex during an outbreak and telling partners.
If you have a sore, get it tested while it’s there. Book a Herpes swab test at a clinic near you or order a home test kit. Our Patient Care Team is available 24/7 on 020 7099 0955.
About this article
Not in the UK? Choose your country from the selector at the top of the page for local tests and prices.
This article originally appeared on 2 February 2009 and was last updated on 3 October 2026.
This article is general information and not a substitute for personal medical advice.
Sources
- Wu Y, Navarro F, Lal A, et al. Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host & Microbe, 2009. https://pmc.ncbi.nlm.nih.gov/articles/PMC2654264/
- Cameron D. Topical treatment wipes out herpes with RNAi. Harvard Gazette, 21 January 2009. https://news.harvard.edu/gazette/story/2009/01/topical-treatment-wipes-out-herpes-with-rnai/
- Wheeler LA, Trifonova R, Vrbanac V, et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. Journal of Clinical Investigation, 2011. https://www.jci.org/articles/view/45876
- World Health Organization, Herpes simplex virus, 30 May 2025. https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus
- British Association for Sexual Health and HIV, UK national guideline for the management of anogenital herpes, 2024. https://www.bashh.org/_userfiles/pages/files/pateletal2024britishassociationofsexualhealthandhivuknationalguidelineforthemanagementofanogenital.pdf
- NHS, Genital herpes, reviewed 27 June 2023. https://www.nhs.uk/conditions/genital-herpes/
- Haleon UK Trading Limited, Zovirax Cold Sore Cream: summary of product characteristics, updated 7 December 2023. https://www.medicines.org.uk/emc/product/27/smpc
- GlaxoSmithKline UK, Zovirax Cream: summary of product characteristics, updated 3 February 2025. https://www.medicines.org.uk/emc/product/5468/smpc
- Centers for Disease Control and Prevention, Herpes, STI treatment guidelines 2021, reviewed 21 September 2022. https://www.cdc.gov/std/treatment-guidelines/herpes.htm
- Marrazzo JM, Rabe L, Kelly C, et al. Tenofovir gel for prevention of herpes simplex virus type 2 acquisition: findings from the VOICE trial. Journal of Infectious Diseases, 2019. https://academic.oup.com/jid/article/219/12/1940/5315462
- Bender Ignacio RA, Perti T, Magaret AS, et al. Oral and vaginal tenofovir for genital herpes simplex virus type 2 shedding in immunocompetent women: a double-blind, randomized, cross-over trial. Journal of Infectious Diseases, 2015. https://academic.oup.com/jid/article/212/12/1949/2911923
- GlaxoSmithKline UK, Valtrex 500mg tablets: summary of product characteristics, updated 30 June 2026. https://www.medicines.org.uk/emc/product/5467/smpc
- GlaxoSmithKline, Valtrex (valacyclovir hydrochloride) prescribing information, revised November 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8e0d8f8-cb73-4206-a484-88f5c4fbd719
- British Association for Sexual Health and HIV, Genital herpes: patient information leaflet, February 2026. https://www.bashh.org/_userfiles/pages/files/resources/herpes_pil_mobilepdf_04.pdf
- GSK, GSK provides update on phase I/II therapeutic herpes simplex virus (HSV) vaccine trial, 11 September 2024. https://www.gsk.com/media/11551/press-release-gsk-provides-update-on-phase-ii-therapeutic-herpes-simplex-virus.pdf
- Moderna, Moderna analyst day highlights pipeline progress and business strategy updates, 20 November 2025. https://www.sec.gov/Archives/edgar/data/1682852/000162828025053318/exhibit9912025analystday.htm
- BioNTech, BNT163-01 clinical trial, read 3 October 2026. https://clinicaltrials.biontech.com/trials/BNT163-01
- AiCuris, Aicuris receives FDA priority review for pritelivir NDA and presents new phase 3 data at ESCMID 2026, 16 April 2026. https://www.aicuris.com/press-release/aicuris-receives-fda-priority-review-for-pritelivir-nda-and-presents-new-phase-3-data-at-escmid-2026/
- Assembly Biosciences, Assembly Biosciences exercises U.S. profit-share option with Gilead for HSV helicase-primase inhibitor program, 8 September 2026. https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-exercises-us-profit-share-option-gilead-hsv
- World Health Organization, Over 1 in 5 adults worldwide has a genital herpes infection, 11 December 2024. https://www.who.int/news/item/11-12-2024-over-1-in-5-adults-worldwide-has-a-genital-herpes-infection-who
- UK Health Security Agency, Sexually transmitted infections and screening for chlamydia in England: 2025 report, 2 June 2026. https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables/sexually-transmitted-infections-and-screening-for-chlamydia-in-england-2025-report




